Purpose: American minority groups have been historically underrepresented in phase III prostate cancer clinical trials despite often having higher risk disease. We analyzed enrollment trends of major racial/ethnic groups in the United States in phase III prostate cancer trials between 2003 and 2014 compared to SEER (Surveillance, Epidemiology and End Results) incidence data. Materials and Methods: Phase III prostate cancer trials primarily enrolling patients from the United States were identified in the ClinicalTrials.gov database. Enrollment trends were analyzed for major racial/ethnic groups. Prostate cancer incidence data from the SEER registry were used to identify enrollment targets. The enrollment difference was determined by calculating the absolute difference between the percent of a racial/ethnic subgroup in the SEER registry population and the percent of that subgroup in the phase III prostate cancer trial population. Results: Among 39 studies identified African American enrollment in therapeutic trials increased across the study period (p <0.001). The enrollment difference for African Americans was e9.0% (95% CI e7.6-e10.5, p <0.001) in 2003 to 2005 and 1.4% (95% CI 0.2e2.6, p ¼ 0.020) in 2012 to 2014. However, African American men were under enrolled in metastatic disease trials (enrollment difference e5.8%, 95% CI e4.8-e6.8, p <0.001). Latino and Asian American men were consistently under enrolled in all trial types. Conclusions: Minority groups in the United States were largely under enrolled in phase III prostate cancer trials between 2003 and 2014. While recruitment efforts may have had an impact, as demonstrated by increased enrollment of African American men, there remains a need to expand recruitment efforts to achieve diversity in trials.
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cancer.
1e3 Hispanic/Latino men with prostate cancer are more likely to be diagnosed with advanced stage prostate cancer and have higher tumor grades compared to nonHispanic Caucasian men. 4 Filipinos, Asian Indians/Pakistanis and Pacific Islanders in the U.S. are also more likely to present with advanced prostate cancer compared with Caucasian men. 5, 6 Numerous factors likely interact and contribute to these disparities, including socioeconomics, access to care, quality of care, environmental factors, genetics and systematic underrepresentation in clinical trials. 7, 8 U.S. minority groups have been historically underrepresented in phase III prostate cancer clinical trials. 9 With low enrollment of minorities, trials often lack statistical power to reveal potential racial and ethnic differences in response to therapy. Acknowledging the need for increased minority inclusion, the Health Revitalization Act of 1993 mandated guidelines for minority inclusion in NIH funded research. 10 The act was amended in 2001 to define minimum standards for collecting and reporting data by sex/gender and race/ethnicity, and again amended in 2017 with a requirement for phase III clinical trials to submit results by sex/ gender and race/ethnicity to ClinicalTrials.gov. 11 Since the enactment in 1993, efforts have been made to increase the enrollment of minorities in prostate cancer trials but it is unclear whether they are having a meaningful impact. 12 In this study we analyzed enrollment trends of major U.S. racial/ethnic groups in phase III prostate cancer clinical trials. We compared the clinical trial enrollment of each group to prostate cancer incidence data from the SEER registry as a suggested enrollment target for racial/ethnic groups. We chose to use the SEER registry because it accounts for cancer diagnoses in a large proportion of the U.S population and is designed to mirror the sociodemographics of the U.S. Census. 13 We hypothesized that the proportion of each U.S. minority subgroup in the clinical trial population would increase across the study period but would not exceed the proportion of each subgroup in the SEER prostate cancer population.
METHODS

Data Collection
We identified phase III prostate cancer clinical trials completed between 2003 and 2014 from the U.S. NLM (National Library of Medicine) ClinicalTrials.gov database. The ClinicalTrials.gov database defines a clinical trial (therapeutic or behavioral) as a clinical study in which participants are assigned to treatment or control groups and researchers evaluate the effects of an intervention on health related outcomes. 14 We defined a therapeutic clinical trial as investigation of a drug, biological agent, dietary supplement, surgical procedure, radiotherapy, device or implant. A behavioral clinical trial was defined as a clinical study evaluating the effects of an intervention on a behavioral outcome. This study was deemed exempt from Institutional Review Board review.
Although the ClinicalTrials.gov database was created in February 2000, only 2 prostate cancer clinical trials were registered from 2000 to 2002. Therefore, we chose to begin the study period in 2003. Trials completed after 2014 were not included because SEER population data on incidence was not yet available after 2014. Trials enrolling participants outside the U.S. and Canada were excluded. Included trials primarily enrolled patients from the U.S. but 8 trials enrolled some patients from Canada. Of these 8 trials only 7.9% of enrollment locations were in Canada.
Trials with incomplete reporting of participant race/ ethnicity were included in analysis if at a minimum they reported the Caucasian population. If a study did not publish any enrollment results by race or ethnicity in the publication(s) or on ClinicalTrials.gov, corresponding authors were contacted electronically with a request for enrollment data. If results were not found in publication(s), on ClinicalTrials.gov or by email request, the trial was excluded ( fig. 1 ).
We used prostate cancer incidence data from the SEER registry to calculate the proportion of disease burden and identify enrollment targets by race/ethnicity and time period. SEER registry locations are strategically chosen to represent the racial/ethnic demographics of the U.S. census. 13 For example, based on the 2010 U.S. Census and SEER data African Americans account for 12.6% and 10.9% of the population, respectively.
We analyzed incidence data on 688,266 patients diagnosed with prostate cancer between 2003 and 2014 using SEER*Stat, version 8. 
Data Analyses
We calculated an enrollment difference using the difference between the percent of a subgroup in the trial population and the percent of that subgroup in the SEER population. The enrollment difference was a positive value if the trial enrollment percent exceeded the SEER population percent, and a negative value if the SEER population percent exceeded the trial enrollment percent. If a study did not report enrollment data on a certain race/ ethnicity, its total population was not included in the calculation of the proportion of trial population represented by that race/ethnicity.
We performed a 2-sample test of proportions comparing the percent of each racial/ethnic subgroup in the trial population to that of the U. To observe changes in enrollment proportions with time we used the chi-square test for trend. We focused the trend analyses on therapeutic trials and excluded behavioral trials because these 2 trial types are considerably different in size, and enrollment methods and settings. Additionally, there were not enough behavioral trials in our study to perform a separate trend analysis. Subanalyses of trend and enrollment difference were also done for therapeutic trials enrolling patients with metastatic disease. All p values were 2-sided with statistical significance considered at p <0.05. All analyses were performed with STATAÒ, version 15.
RESULTS
A total of 77 phase III prostate cancer clinical trials with enrollment locations in the U.S. were completed between 2003 and 2014, and registered with the NLM ClinicalTrials.gov database. Of the trials 26 did not meet eligibility criteria ( fig. 1 ). Of the remaining 51 trials 12 did not provide available data on participant race or ethnicity in the study publications, on ClinicalTrials.gov or by emailing a data request to the corresponding authors.
Included in study were 39 phase III prostate cancer clinical trials with a total clinical trial population of 20,820 participants (see table) . Of the 35 therapeutic trials 27 were drug trials, 2 were dietary supplement trials, 2 tested biological agents, 2 were surgical trials, 1 tested a medical device and 1 was a radiation therapy trial (supplementary Appendix, table, and figs. 1 and 2, http://jurology. com/). In 17 trials patients with localized and/or regional disease were enrolled (43.6%) and 11 trials enrolled patients with metastatic disease (28.2%). Five trials enrolled patients without prostate cancer and accounted for 30.7% of the total trial population of the study (see table) . Three of the 5 trials enrolling patients without prostate cancer were behavioral interventions and 2 studied preventive drug therapies.
Five of the 35 trials (14.3%) resulting in publication published enrollment data only on Caucasian patients and categorized nonCaucasian patients as other or unknown. In addition, 28 trials (80.0%) published enrollment data on African Americans, 18 (51.4%) provided data on Latinos and 18 (51.4%) provided data on Asian Americans. Only 3 of all study trials (7.7%) provided enrollment results stratified by race and ethnicity in the ClinicalTrials.gov database.
Comparison of Surveillance, Epidemiology and End Results, and Trial Populations (2003 to 2014)
Caucasian patients accounted for 69.5% of the prostate cancer incidence in the SEER registry and represented 77.8% of the total trial population, 82.0% of the therapeutic trial population and 63.1% of the behavioral trial population (p <0.001, fig. 2 ). African American patients represented 14.2% of the prostate cancer incidence in the SEER registry, 17.9% of the total trial population (p <0.001), 14.3% of the therapeutic trial population (p ¼ 0.72) and 30.4% of the behavioral trial population (p <0.001). Latino patients accounted for 8.8% of the prostate cancer incidence in the SEER registry, 4.2% of the total trial population, 3.7% of the therapeutic trial population and 5.9% of the behavioral trial population (p <0.001). Asian American patients accounted for 4.6% of the prostate cancer incidence in the SEER registry, 1.0% of the total trial population and 0.8% of the therapeutic trial population (p <0.001).
Enrollment Trends by 3-Year Intervals
The proportion of Caucasian patients was consistently above SEER based target enrollment in therapeutic trials across the 4 study intervals. However, this proportion decreased with time with a significant test for trend (p <0.001, fig. 3, A) . The proportion of African American men in the therapeutic trial population progressively increased during the study period (p <0.001, fig. 3, B) . The proportion of Latinos did not significantly change (p <0.46, fig. 3 , C) and the proportion of Asian Americans modestly increased (p ¼ 0.035, fig. 3, D) .
The Caucasian enrollment difference decreased across the study period from 20.4% (95% CI 18.8e22. (fig. 4, B) . Latino and Asian American men were consistently below SEER based target enrollment. The Latino enrollment difference ranged from e3.9% to e5.7% (fig. 4, C) and the Asian American enrollment difference ranged from e3.4% to e3.9% ( fig. 4, D) .
In the subanalysis of therapeutic trials enrolling patients with metastatic disease Caucasian patients represented 65.0% of the SEER population with distant disease and 84.7% of the metastatic trial population from 2003 to 2014. Across all years African American men accounted for 17.5% of the SEER population with distant disease and 11.7% of the metastatic trial population. The proportion of Caucasian enrollment decreased with time and the test for trend was significant (p <0.001, fig. 5, A) . African American enrollment trended toward increased enrollment (p ¼ 0.014, fig. 5, B) . The African American enrollment difference was e13.1% (95% CI e10.4-e15. NIH funded research. The NIH amended the act in 2001 to include guidelines for stratifying study results by sex/gender and race/ethnicity, and it has recently mandated reporting of baseline enrollment data by race/ethnicity for publication on ClinicalTrials.gov. 11 The FDA (Food and Drug Administration) designated 2016 the Year of Diversity in Clinical Trials to encourage minority inclusion. 15 In spite of these efforts our findings suggest that African American men are under enrolled in advanced disease trials, and Latino and Asian American men are under enrolled in all types of trials. However, government mandates and support for diversity may have impacted enrollment as demonstrated by significantly increased enrollment of African Americans in therapeutic trials.
Our results demonstrate that investigators are not sufficiently reporting data by race/ethnicity. Only 3 studies in this analysis reported enrollment results stratified by race and ethnicity in ClinicalTrials.gov. More than 14% of studies resulting in publication did not mention African American enrollment and simply categorized patients as Caucasian and other. It has long been established that African American men have a higher incidence and risk of death from prostate cancer, and so it is concerning that a significant percent of trials do not report African American enrollment. Additionally, only half of the trials published data on Latino and/or Asian American enrollment, which are the fastest growing racial/ ethnic groups in the U.S. 16 Future trials should oversample racial/ethnic minority groups above SEER incidence rates to allow for statistically powered race stratified or subgroup analyses. 17 Additionally, funding agencies such as the NIH should identify ways to enforce enrollment and publication mandates.
To optimize minority enrollment researchers must address limited access to care at academic centers, patient mistrust of health care systems, researcher biases, and cultural and linguistic barriers to enrollment. Therapeutic cancer trials at large cancer centers may be less accessible to minority communities. 18 Studies have also shown that minorities are more likely to participate in trials when research personnel are from the same racial, cultural or linguistic background, or when they are enrolled through trusted institutions such as places of worship and community based organizations. Biases among clinical research teams must also be addressed. For example, some researchers believe that minorities have little interest in research participation and, therefore, they do not recruit, although studies show that minorities are willing to participate in clinical trials at the same rate as their Caucasian counterparts.
23e25 Our finding that behavioral trials have had more success in recruiting minorities than therapeutic trials may reflect differences in investigator beliefs, study design and enrollment location.
This study has some limitations. 1) SEER incidence data as enrollment targets for clinical trials may underestimate the burden of disease among minorities since there are areas that do not participate in the SEER program (eg Detroit) and SEER data cover only 34.6% of the total U.S. population. 26e28 2) We excluded 12 trials because they did not publish any enrollment data by race/ ethnicity or provide data when it was requested via email correspondence. Also, many of the included trials had incomplete reporting. There is potential for selection bias since studies not reporting enrollment data may have inadequate inclusion of minorities. Therefore, our study findings may overestimate minority enrollment.
3) This study did not account for substantial diversity in racial/ethnic categories by disaggregating data among Asian American or Latino patients. 4) We did not use individual patient data but rather relied on summary statistics.
Despite these limitations this study has several strengths. To our knowledge it is the first investigation of prostate cancer clinical trial enrollment using SEER incidence data and trial enrollment data to evaluate enrollment disparities. It provides researchers with a suggested framework to establish clinical trial enrollment targets. It also evaluates reporting on race/ethnicity in publications and on ClinicalTrials.gov, which is a valuable database for providers, patients and researchers to access trial results and information.
CONCLUSIONS
Much work remains to improve the enrollment of U.S. minority groups in phase III prostate cancer clinical trials. Efforts to improve enrollment may have led to increased inclusion of African American men in therapeutic trials as a whole. However, they face under enrollment in advanced disease trials. Asian American and Latino patients also face persistent under enrollment across all trial types. Investigators should work to improve recruitment and enrollment efforts, and report enrollment data by race and ethnicity so that patients, providers and researchers can better grasp the generalizability and applicability of study results. 
